Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-04
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Carbapenemase Gene Spread in CREC, 2022–2024

    2026-10-08

    Carbapenemase Gene Spread in CREC, 2022–2024

    Study Background and Research Question

    Carbapenem-resistant Enterobacter cloacae complex is an important component of the broader carbapenem-resistant Enterobacteriaceae problem. Its clinical significance is not explained by resistance phenotype alone. Carbapenemase-encoding genes can be located on plasmids, chromosomes, or mobile genetic structures, creating different opportunities for persistence within bacterial lineages and movement between organisms.

    The reference study by Chen, Yan, and colleagues addresses this gap through a multicenter analysis of 54 carbapenem-resistant E. cloacae isolates collected from eight teaching hospitals in Guangdong Province, China, between December 2022 and June 2024. The authors ask how frequently carbapenemase-encoding genes occur, where those genes are located, whether they show evidence of transferability, which mobile genetic elements accompany them, and how the isolates are related by molecular typing. The paper is available as an open-access report in BMC Microbiology.

    The timing is also relevant. The authors frame the work against the disruption, altered antibiotic use, and complex patient-care pressures associated with the COVID-19 period. However, the study is not a direct assessment of pandemic causality. Its contribution is a contemporary snapshot of resistance mechanisms and dissemination potential in a defined regional hospital network.

    Key Innovation from the Reference Study

    The principal innovation is the integration of several evidence layers rather than treating carbapenem resistance as a single phenotype. The study combines gene detection, assessment of chromosomal versus plasmid localization, antimicrobial susceptibility comparisons, transferability testing, mobile-element characterization, and strain typing. This design allows the authors to distinguish several questions that are often conflated: whether a resistance gene is present, whether it is positioned on a potentially mobile replicon, whether a strain belongs to a broader genotype, and whether isolates from different hospitals may share related resistance architectures.

    That integrated perspective is especially important for blaNDM-1, the dominant carbapenemase gene in this collection. A gene found on both chromosome and plasmid has a different epidemiological interpretation from a gene detected only in a chromosome or only in a plasmid. Similarly, a high frequency of successful laboratory transfer indicates genetic mobility under the study’s test framework, but it does not by itself prove that transfer occurred between patients or hospital wards.

    The paper therefore contributes more than a prevalence estimate. It presents CREC as a layered system in which resistance determinants, mobile genetic elements, bacterial lineages, clinical settings, and specimen sources may interact.

    Conceptual Study Design and Evidence Scope

    The study used a hospital-based isolate collection and applied complementary molecular and phenotypic approaches. Polymerase chain reaction was used to identify carbapenemase-encoding genes, while a variable-temperature sodium dodecyl sulfate plasmid-elimination approach helped assess whether detected genes were associated with plasmids or chromosomes. These methods address genetic location conceptually; they should not be interpreted as complete physical mapping of every resistance locus.

    Antimicrobial susceptibility was compared between isolates with and without detected carbapenemase-encoding genes using broth microdilution results reported by the authors. The study also evaluated whether resistance determinants could be transferred in a plasmid-conjugation framework. This is evidence about potential horizontal mobility under defined laboratory conditions, not a measurement of transfer frequency in patients, wastewater, or hospital surfaces.

    Mobile genetic elements were examined to identify structures associated with the resistance genes. Finally, ERIC-PCR and NTSYS-based analysis grouped the 54 isolates into molecular genotypes. This typing layer provides a way to examine relatedness, but it is not equivalent to whole-genome epidemiology. It has lower resolution than sequence-based approaches and cannot alone establish a transmission chain.

    Overall, the study design is best viewed as a regional, cross-sectional molecular epidemiology investigation. It is strong for describing the resistance architecture of the sampled isolates and for generating hypotheses about dissemination. It is less suited to estimating population-wide prevalence, reconstructing patient-to-patient transmission, or determining whether particular clinical exposures caused gene acquisition.

    Core Findings and Why They Matter

    High prevalence of carbapenemase-encoding genes

    Carbapenemase-encoding genes were detected in 46 of 54 isolates, corresponding to 85.19% of the collection. The most prominent pattern involved blaNDM-1. Eighteen isolates, or 33.33%, carried blaNDM-1 on both chromosomes and plasmids, while 25 isolates, or 46.30%, carried blaNDM-1 exclusively on plasmids. Two isolates contained only blaIMP on plasmids, and one contained both blaNDM-1 and blaKPC-2 on plasmids.

    These results support the authors’ conclusion that blaNDM-1 was the predominant carbapenemase determinant in this sample and that plasmid-associated carriage was common. The combination of chromosomal and plasmid localization also suggests that CREC resistance architecture is heterogeneous. It would be an overinterpretation, however, to infer that every plasmid-associated gene was actively circulating across hospitals.

    Association with broader drug resistance

    The carbapenemase-positive group showed significantly higher resistance rates than the carbapenemase-negative group for imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin. These comparisons indicate that carbapenemase carriage occurred within a multidrug-resistant background rather than as an isolated change affecting carbapenems alone.

    The findings do not demonstrate that each gene directly caused resistance to every tested agent. Resistance phenotypes can reflect additional mechanisms, including permeability changes, efflux, target alterations, and other beta-lactamases. The most defensible interpretation is that carbapenemase-positive isolates represented a particularly resistant subset in this hospital-derived collection.

    Evidence for genetic mobility

    Transfer-associated testing produced evidence of high mobility potential: 44 of 46 carbapenemase-positive isolates yielded a reported transfer outcome, for a success rate of 95.65%. The reported rates were 95.45% for blaNDM-1 and 100% for the two blaIMP-positive isolates. No transfer was observed for the single blaKPC-2 isolate in the reported experiment.

    These results make plasmid-associated blaNDM-1 a central concern for surveillance. They also illustrate why gene mobility should be interpreted probabilistically. A laboratory transfer result supports the capacity for horizontal dissemination under the study framework, but it does not establish how frequently such events occur in clinical environments or whether they explain the distribution of isolates among the eight hospitals.

    Mobile elements and strain relatedness

    Six types of mobile genetic elements were identified. ISEcp1 was the most prevalent, occurring in 47 of 54 isolates, or 87.04%. Isolates carrying four mobile-element types simultaneously were the most common pattern, accounting for 22 of 54 isolates, or 40.74%. This supports a view of resistance dissemination as a composite process involving multiple genetic vehicles rather than a single universal plasmid.

    ERIC-PCR and NTSYS analysis divided the isolates into 17 genotypes. Types E and G were each represented by 11 isolates, or 20.37%, and were reported across different departments in five hospitals. Two type E isolates shared a Dice coefficient of 100%. These observations suggest both diversity and possible clusters of closely related organisms. They do not, without patient-level timelines and higher-resolution genomic data, prove a single transmission event.

    Clinical distribution patterns

    The highest detection frequencies occurred among male patients, older adults, respiratory medicine cases, and sputum specimens: 64.81%, 72.22%, 20.37%, and 33.33%, respectively. These are descriptive distributions within the study sample, not risk estimates. They may reflect referral patterns, underlying illness, sampling practices, or department-specific patient populations as well as differences in transmission.

    Comparison with Existing Internal Articles

    The internal article Levofloxacin in Mechanistic Research: Beyond Antibacteria approaches resistance research from the perspective of a synthetic fluoroquinolone antibiotic and its molecular targets. Its scope is therefore mechanistic and application-oriented, whereas Chen et al. focus on carbapenemase genes, mobile genetic elements, and isolate relatedness. The two perspectives are complementary: susceptibility results provide a phenotypic signal, while gene-localization and typing data help explain how resistance may persist or spread.

    A second contextual comparison is the internal review Ceftolozane/Tazobactam: Mechanism and Evidence. That article emphasizes an antimicrobial combination, susceptibility interpretation, pharmacology, and clinical-trial context. The Guangdong study addresses a different evidence question: not whether a treatment is effective, but how resistance determinants are distributed and how readily they may be mobilized. Neither article should be used as a substitute for organism-specific susceptibility data or local epidemiology.

    Limitations and Transferability

    The principal limitation is sample scope. Fifty-four isolates from eight teaching hospitals provide useful regional surveillance evidence, but they cannot establish prevalence across all hospitals in Guangdong, all clinical departments, or the wider community. The sampling period also captures a defined interval rather than long-term trends before, during, and after the pandemic.

    The study’s molecular methods provide important evidence but have resolution boundaries. ERIC-PCR can identify broad relatedness but is less discriminating than whole-genome sequencing. Plasmid-elimination and PCR-based localization support an interpretation of chromosomal or plasmid association, yet detailed plasmid structures, copy numbers, insertion sites, and complete genetic contexts may require sequencing-based confirmation.

    Transfer experiments demonstrate potential mobility, not observed transmission in care settings. Likewise, the presence of ISEcp1 or several mobile elements does not alone show that a particular element caused the spread of a gene. Clinical variables, prior antibiotic exposure, patient movement, environmental sampling, and ward-level timelines would be needed to test causal transmission hypotheses.

    Accordingly, the strongest application of this paper is as a surveillance and hypothesis-generating reference. Its results support attention to blaNDM-1, plasmid-associated resistance, and multidrug-resistant CREC, while local laboratories and infection-control programs should interpret the findings alongside their own validated data.

    Research Support Resources

    For researchers reviewing the susceptibility component of this paper, Levofloxacin (SKU B1959) is a material mentioned in the source study. The supplied product dossier also describes separate contexts involving an osteoblast growth inhibition assay, calcium deposition inhibition, and a chondrocyte glycosaminoglycan synthesis study; those applications are not findings of Chen et al. and should be evaluated as distinct research questions. The reference paper remains the appropriate source for interpreting carbapenemase prevalence, resistance associations, and dissemination potential.